Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2010

View Archived Issues

Achillion selects ACH-2928 as lead candidate against HCV infection

Clinical phase III data presented on linagliptin in type 2 diabetes

IL-7 gene SNPs correlate with rapid HPV clearance in HIV-1-infected subjects

KIF5A, CD226 and SH2B3 gene variants linked to autoimmune diseases

New PET tracer [18F]-MK-3328 for AD diagnosis advances in phase I trial

Genticel's phase I ProCervix trial in HPV-infected women cleared in Belgium

Cytokinetics receives NINDS grant for CK-2017357 development

Tibotec submits NDA for HIV therapeutic TMC-278 to FDA

Onyx presents phase IIb data on carfilzomib in multiple myeloma

FDA grants orphan drug status to BiovaxID for mantle cell lymphoma

Prana Biotechnology claims new quinazolinones for PD

AVEO pays XOMA milestone after starting phase II AV-299 trial

Xenon Pharma discloses new voltage-gated sodium channel blockers

Health Canada clears phase II iCo-007 trial in diabetic macular edema

Canadian scientists discover new agents to deliver antineoplastic therapy

Arena identifies novel prostanoid IP1 receptor agonists

U.S. researchers present new PKR1/PKR2 receptor antagonists

FDA approves Daiichi Sankyo's Tribenzor for hypertension

Titan Pharma receives NIH grant to develop long-term PD therapy

Ampio completes negotiations to acquire DMI BioSciences

QRxPharma to submit MAA for MoxDuo IR analgesic in Germany

CF-102 decreases HCV load in phase I/II trial in liver cancer

FDA posts briefing materials on AstraZeneca's ticagrelor NDA

CHMP issues positive opinion on Arixtra use for superficial vein thrombosis

FIT-06 shows promise in treatment-naive HIV-1-infected subjects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...